News

Contact Us
News icon

News

A New Plant Virus Has Been Chosen As a Candidate for Covid-19 Vaccine

May, 2021

News inner img

 

The new adjuvant vaccine system, with its two dose regime will be functional to induce greater immune response along with very little reatogeniticity among the humans.

Recent phase-2 spread of the super infective, triple mutant SARS-Cov-2, has taught individuals in a mood big way the importance of vaccination, to stop the progression of this deadly virus. Although from January 2021 many vaccine are available functioning both safety and efficiently across the world, related to Covid-19. However, effectively to these vaccines remain questionable against curbing the effect of the newly mutated forms of SARS-CoV-2. Thus, the scientists are pushing towards newer source and methods for the vaccine production.

Recently a plant-produced viral practice is isolate and after certain level of testing it has been chosen as a candidate for vaccine production. Generally a vaccine works by inducing both humoral and cell mediated immune response in the human body through which the body produces both memory cells and other cytoxic cells, as a protection to the disease. The aforesaid vaccine is tested and showed efficiency in activating both Cell-Mediated and Humoral system of immunity.

This new plant based vaccine candidate consists of Covid-like structural particles displaying a similarity with the spike protein as seen in SARS-CoV-2. The protein are embedded on nano-lipid bilayer. These mimicking viral particles are actually found in Nicotiana bethamiana plant. The vaccine was used with oil-in-water adjuvant, and after incorporation of the vaccine, a strong transient immune function was noticed. It antigen produced by this adjuvant vaccine also induce a strong adaptive immune response in both humoral and cellular aspect.

The study was done on mainly in the age group of 18 to 64 years with two doses given at an interval of 21 days. Test result proved minimum effective antibody response in both the younger adults and older adults as well, with very less reatogeniticity in the older adults. Out of these two population group most of them experienced a large increase in the production of neutralising antibody. Thus from this study researchers concluded that this new adjuvant vaccine system, with its two dose regime will be functional to induce greater immune response along with very little reatogeniticity among the humans.

Contact us

Office Locations

Sales Office

U.S.Office | Coherent Market Insights United States of America

Coherent Market Insights Pvt Ltd, 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Asia Pacific Intelligence Center

U.S.Office | Coherent Market Insights India

Coherent Market Insights Pvt Ltd, 203, 2nd Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.